ISRCTN ISRCTN61788850
DOI https://doi.org/10.1186/ISRCTN61788850
Secondary identifying numbers 18696
Submission date
22/04/2015
Registration date
24/04/2015
Last edited
10/03/2020
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Nutritional, Metabolic, Endocrine
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
Hepatitis C is a virus that can infect the liver. Most people do not have any symptoms as they do not arise until the virus has caused significant damage to the liver. When they do occur, they tend to be vague and similar to a number of other conditions. They include flu-like symptoms, feeling tired and depression. People can get infected with the virus if they come into contact with the blood of an infected person, for example, by sharing drug needles. Due to the condition not having any obvious symptoms, regular testing is recommended for people considered to be in a high risk group, for example drug users. Here, we want to see if we can increase testing and diagnosis of people at an increased risk of hepatitis C virus (HCV) infection in the primary care setting (for example, at GP surgeries).

Who can participate?
Patients that have been approached by their GPs for HCV testing and attending a participating GP practice.

What does the study involve?
Participating GP practices are randomly allocated into one of two groups. Those in group one are given a complex intervention (or programme) consisting mainly of targeted case finding and inviting high risk patients to the practice for a test. Those in group two are not given the intervention and carry on as usual. We also look at how acceptable both patients and health care providers find the intervention and identify potential modifications that may be required to encourage HCV testing in primary care. At the end of the study we compare HCV testing, diagnosis, assessment and treatment rates between intervention and control sites. If the interventions are acceptable, work well and cost-effective then we will encourage their roll-out in primary care.

What are the possible benefits and risks of participating?
Some high-risk HCV patients registered at the intervention practices may be given an earlier test or diagnosis as a result of the practice being involved in the study. For the participants involved in the qualitative study, although there may not be any direct benefit from taking part, they will be helping to improve future services and treatment accessibility for people living with HCV. We do not foresee any potential risks to the patients. For the qualitative interviews, the only risk we foresee is related to patient inconvenience related to consent procedures and participation in the interviews.

Where is the study run from?
Primary care practices in the South West of England (UK)

When is the study starting and how long is it expected to run for?
June 2015 to December 2017

Who is funding the study?
Department of Health - National Specialised Commissioning Team (UK)

Who is the main contact?
Dr Kirsty Roberts

Contact information

Dr Kirsty Roberts
Scientific

School of Social and Community Medicine
Oakfield House
Oakfield Grove Bristol
Bristol
BS8 2BN
United Kingdom

Study information

Study designRandomised; Interventional and Observational; Design type: Diagnosis, Screening, Qualitative
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)GP practice
Study typeDiagnostic
Participant information sheet Not available in web format, please use the contact details to request a participant information sheet
Scientific titleEvaluation of interventions designed to increase diagnosis and treatment of patients with Hepatitis C virus infection in primary care
Study acronymHepCATT
Study objectivesThis study will determine whether we can increase testing and diagnosis of individuals at increased risk of HCV infection in primary care with a complex intervention consisting mainly of targeted case finding and inviting high risk patients to the practice for a test. We will also conduct a nested qualitative study with patients and health-care providers to assess the acceptability of the intervention and identify potential modifications that may be required to encourage HCV testing in primary care.
Ethics approval(s)15/SW/0094
Health condition(s) or problem(s) studiedTopic: Primary Care; Subtopic: Primary care; Disease: All Diseases
InterventionHCV test algorithm: The HCV test algorithm will run a search on GP systems to generate a list of individuals with risk markers for HCV infection
1. Increasing patient awareness, displaying Hepatitis C posters and leaflets in the practice waiting rooms
2. Increasing practice awareness
3. An offer of educational training on HCV for practice staff
Intervention typeOther
Primary outcome measureNumber/proportion of patients tested for HCV; Timepoint(s): 12 months
Secondary outcome measures1. Cost of case finding and testing; Timepoint(s): 12 months
2. Incremental cost per case detected; Timepoint(s): 12 months
3. Number and proportion testing positive (yield); Timepoint(s): 12 months
4. Number/ proportion attending for assessment; Timepoint(s): 12 months
5. Number/ proportion initiating treatment; Timepoint(s): 12 months
6. Number/ proportion referred for specialist assessment; Timepoint(s): 12 months
Overall study start date01/07/2014
Completion date31/12/2017

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participantsPlanned Sample Size: 920; UK Sample Size: 920
Key inclusion criteriaFor patient interviews:
1. Individuals approached by their GP for a HCV test in participating intervention practices who are aged over 18 years old
2. Able to provide informed consent and who have a telephone they can be contacted on
Key exclusion criteriaFor the patient interviews:
Unable to provide informed consent
Date of first enrolment01/06/2015
Date of final enrolment31/12/2016

Locations

Countries of recruitment

  • United Kingdom

Study participating centres

Bristol Primary Care Trust (lead)
Bristol
-
United Kingdom
North Somerset Primary Care Trust
Somerset
-
United Kingdom
South Gloucestershire Primary Care Trust
Gloucestershire
-
United Kingdom

Sponsor information

University of Bristol (UK)
University/education

Department of Social Medicine
Canynge Hall
Whiteladies Road
Bristol
BS8 2PR
England
United Kingdom

ROR logo "ROR" https://ror.org/0524sp257

Funders

Funder type

Government

Department of Health - National Specialised Commissioning Team; Grant Codes: 015/0309

No information available

Results and Publications

Intention to publish date01/07/2019
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
Publication and dissemination planWe plan to publish the results of the trial in a peer-reviewed journal and at national conferences.
IPD sharing planThe datasets generated during and/or analysed during the current study will be available upon request from Prof. Matthew Hickman (matthew.hickman@bristol.ac.uk), the CI for HepCATT and the data controller. Access to this data will be available shortly. The anonymised data set will be stored in the research data facility at the University of Bristol.

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Protocol article protocol 29/07/2016 Yes No
Results article results 30/07/2020 26/02/2020 Yes No
Results article cost-effectiveness results 26/02/2020 10/03/2020 Yes No
HRA research summary 28/06/2023 No No

Editorial Notes

10/03/2020: Publication reference and IPD sharing statement added.
26/02/2020: Publication reference added.
17/01/2020: The overall trial end date was changed from 30/04/2018 to 31/12/2017.
04/04/2019: The intention to publish date was added.
13/12/2017: The overall trial end date was changed from 31/12/2016 to 30/04/2018.
01/08/2016: Publication reference added.